| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-069 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 第五届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 三诺生物传感股份有限公司（以下简称"公司"） 第五届董事会第二十次 会议于 2025 年 8 月 27 日（星期三）上午 10 时在公司会议室以现场结合通讯方 式召开。本次会议的通知已于 2025 年 8 月 17 日通过书面或电子邮件方式送达全 体董事。应出席本次会议的董事 7 人，实际出席本次会议的董事 7 人，分别为李 少波先生（兼任总经理）、李心一女士、车宏菁女士、李晖（LI HUI）先生、袁 洪先生、康熙雄先生、陈纪正女士。会议由董事长李少波先生召集并主持，公司 监事、高级管理人员列席了会议。会议的召集、召开符合《公司法》及《公司章 程》《公司董事会议事规则》的规定。 二、会议审议情况 本次会议采用现场和通讯表决方式进行表决，经与会董事认真审 ...

Core Viewpoint - Sanofi Biotech has established itself as a leader in the diabetes management sector, focusing on innovative solutions and expanding its product offerings to enhance patient care and health outcomes [1][2]. Group 1: Company Overview - Sanofi Biotech is recognized as the "first stock" in China's blood glucose industry and ranks as the fourth largest blood glucose meter company globally [1]. - The company serves over 25 million users worldwide, with products and services available in 187 countries and regions [1]. - In China, more than 50% of individuals who self-monitor their blood glucose levels use Sanofi's products [1]. Group 2: Strategic Direction - The company is extending its focus into diabetes medical services, emphasizing a digital management model that integrates biosensing, IoT, smart healthcare, and lifestyle guidance [2]. - Sanofi aims to shift diabetes management from a disease-centered approach to a health-centered approach, as outlined in the National Health Commission's plan for diabetes prevention and treatment from 2024 to 2030 [2]. Group 3: Product Development - Continuous Glucose Monitoring (CGM) systems are identified as a critical area for strategic development, providing comprehensive and reliable blood glucose information [2]. - Sanofi has completed the development of its second-generation CGM product, which has been launched domestically and received EU CE-MDR certification for sales in EU-recognized countries [3]. - The company is integrating artificial intelligence into chronic disease management, with its SinoGPT technology already operational [3]. Group 4: Future Investments - A global R&D center is set to be established, with an anticipated investment of 500 million yuan, focusing on the biosensing industry chain [3]. - Future R&D efforts will include artificial pancreas and insulin pump technologies to provide comprehensive solutions for chronic disease management [3].

三诺生物最新股价报21.09元，较前一交易日上涨0.43%。盘中最高触及21.17元，最低20.92元，成交金 额达2.81亿元。公司当前总市值118.16亿元，市盈率为40.96倍。 来源:金融界 资金流向方面，三诺生物当日主力资金净流出167.09万元，近五个交易日累计净流入2157.98万元。 风险提示：本文所提及个股仅作客观陈述，不构成任何投资建议。市场有风险，投资需谨慎。 作为医疗器械行业的重要企业，三诺生物专注于血糖监测产品的研发与生产。公司产品覆盖全球187个 国家和地区，服务超过2500万用户。在中国市场，超过50%的糖尿病自我监测人群使用三诺产品。 公司近期动态显示，位于湖南长沙的三诺全球研发中心即将落成。该中心预期投入5亿元，将重点开展 可穿戴设备、高端植入医疗设备等领域的研发工作。公司已完成第二代持续葡萄糖监测系统产品的研发 并实现国内上市，该产品同时获得欧盟CE-MDR认证。副董事长李心一表示，未来将在人工胰腺、胰岛 素泵等技术领域加大研发投入。 ...

近日，三诺生物（300298）副董事长李心一在2025西普会上接受记者采访时表示，创业初期让糖尿病患 者用上血糖仪只是第一步，随着不断发展，公司一直积极向糖尿病医疗服务领域延伸。位于湖南长沙的 三诺全球研发中心即将落成，接下来会持续推动可穿戴、高端植入医疗设备的研究开发。 作为中国血糖行业"第一股"，三诺生物已成为全球第四大血糖仪企业。目前公司全球用户超过2500万， 产品和服务覆盖187个国家和地区。根据中康资讯的最新数据，在中国有超过50%的糖尿病自我监测人 群使用着三诺的产品。 "对三诺来说，让糖尿病患者用上血糖仪只是第一步。"李心一表示，"三诺一直积极向糖尿病医疗服务 领域延伸，打造'生物传感+物联网+智慧医疗+健康生活方式引导'的糖尿病及相关慢病数字管理模式， 聚焦动态血糖仪的创新研发。" 糖尿病全病程管理对糖尿病患者而言至关重要，国家卫生健康委印发的《健康中国行动—糖尿病防治行 动实施方案（2024—2030年）》明确提出推进糖尿病防治从"以治病为中心"向"以健康为中心"转变的思 路，要及早干预治疗糖尿病肾病、糖尿病视网膜病变、糖尿病足等并发症，延缓并发症进展，降低致残 率和致死率。 在海外已成主 ...

Group 1: Institutional Research and Shareholder Activity - The top twenty companies with the most institutional research in the last 30 days include Dongpeng Beverage, Zhongchong Co., Hikvision, Defu Technology, and Xinyi Technology[5] - In the last five days, the most researched companies include Nanwei Medical, Anjisi, Jinchengzi, Xinqianglian, and Baiya Co.[5] - Among the top twenty companies with institutional research in the last 30 days, 12 companies had 10 or more rating agencies, including Dongpeng Beverage, Zhongchong Co., and Hikvision[5] Group 2: Shareholder Buybacks - From August 11 to August 15, 2025, 51 companies announced buyback progress, with 10 having 10 or more rating agencies, and only 2 companies (Baolong Technology and Fuanna) had buyback amounts exceeding 1% of their market value[25] - From January 1 to August 15, 2025, 1,662 companies announced buyback progress, with 364 having 10 or more rating agencies, and 99 companies had buyback amounts exceeding 1% of their market value[27] Group 3: Shareholder Increase Activity - From August 11 to August 15, 2025, only 5 companies with significant shareholder increases had amounts below 1% of their market value[19] - From January 1 to August 15, 2025, 251 companies announced significant shareholder increases, with 67 having 10 or more rating agencies, and 19 companies had amounts exceeding 1% of their market value[21]

Core Insights - The company has launched several new products since 2025, including the Yuzhun SC801/SC801Air blood glucose meter and the Zhangyou M101/M101air blood uric acid and lipid meter, which have expanded its product application areas and target demographics [1] - The company has also upgraded existing products, such as the second generation of the San Nuo dynamic blood glucose meter and the EA-19 Pro uric acid and blood glucose meter, optimizing its product structure and industrial layout [1] - Future product launches will focus on multi-parameter monitoring and chronic disease management to meet user needs for family health [1] - In Q1 2025, the company reported revenue of 1.042 billion yuan, a year-on-year increase of 2.76%, while the net profit attributable to shareholders was 72 million yuan, a year-on-year decrease of 10.90% [1]

Group 1: Institutional Research on Popular Companies - The top twenty companies with the highest number of institutional research visits in the past 30 days include Dongpeng Beverage, Zhongchong Co., Hikvision, Defu Technology, and Xinyi Technology [10][11] - In the last five days, the most popular companies for institutional research include Nanwei Medical, Anjisi, Jinchengzi, New Strong Union, and Baiya Co. [10][11] - Among the top twenty companies in the past 30 days, twelve companies had ten or more rating agencies, including Dongpeng Beverage, Zhongchong Co., Ninebot, Baiya Co., Hikvision, Jereh, Xinyi Technology, Hongfa Technology, Nanwei Medical, Baijia Shenzhou, Huaming Equipment, and Shijia Photon [10][11] - Companies such as Xinyi Technology, Dongpeng Beverage, Zhongchong Co., and Ninebot are expected to see significant growth in net profit attributable to shareholders in 2024 compared to 2023 [10][11] Group 2: Shareholder Increase and Buyback Situations - From August 11 to August 15, 2025, five companies announced significant shareholder increases, but the average proposed increase amount was less than 1% of the market value on the announcement date [14] - From January 1 to August 15, 2025, a total of 251 companies announced shareholder increases, with 67 having ten or more rating agencies. Among these, 19 companies had an average proposed increase amount exceeding 1% of the latest market value, including Xinjie Energy, Tunnel Co., Sailun Tire, and Wanrun Co. [15] - During the same period, 1,662 companies announced buyback progress, with 364 having ten or more rating agencies. Among these, 99 companies had a proposed buyback amount exceeding 1% of the market value [19] Group 3: Buyback Progress - From August 11 to August 15, 2025, 51 companies announced buyback progress, with 10 having ten or more rating agencies. Only two companies, Baolong Technology and Fuanna, had a proposed buyback amount exceeding 1% of the market value [18] - From January 1 to August 15, 2025, 99 companies were in the board proposal stage for buybacks, including Liu Gong, Sanor Biotech, Shantui, Haixing Electric, Jiayi Co., and Gaoneng Environment [19] Group 4: Institutional Fund Flow - During the week of August 11 to August 15, 2025, sectors such as power equipment, electronics, real estate, non-bank financials, public utilities, computers, home appliances, building materials, light industry manufacturing, and banking received net inflows from institutional funds [24]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗器械板块主力资金净流出6.22亿元，游资资金净流入8454.45万元，散户资 金净流入5.38亿元。医疗器械板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300049 | 福瑞股份 | 1.46 Z | 11.88% | -1.05 Z | -8.52% | -4138.97万 | -3.36% | | 300003 | 乐普医疗 | 1.21 Z | 7.97% | -5108.00万 | -3.37% | -6962.47万 | -4.59% | | 600645 | 中源协和 | 9348.49万 | 9.75% | -3949.64万 | -4.12% | -5398.85万 | -5.63% | | 688271 | 联影医疗 | ...

Company Overview - Sanofi Bio is engaged in the research, production, and sales of blood glucose monitoring systems and related chronic disease management products [1] - The company holds a significant market position in the diabetes monitoring sector, offering both home-use and medical-grade blood glucose monitoring devices [1] Stock Performance - As of August 14, 2025, Sanofi Bio's stock price is 20.78 yuan, down 1.38% from the previous trading day [1] - The stock opened at 21.10 yuan, reached a high of 21.14 yuan, and a low of 20.62 yuan, with a trading volume of 128,900 hands and a transaction amount of 269 million yuan [1] Financial Flow - On August 14, the net inflow of main funds was 7.8041 million yuan, with a cumulative net inflow of 16.4178 million yuan over the past five days [1] Business Focus - The company clarified on its investor interaction platform that it has not engaged in brain-computer interface-related businesses or the supply of medical-grade electroencephalogram signal collection devices [1] - Sanofi Bio's exploration in the field of artificial intelligence is primarily focused on AI and chronic disease management [1]

每经AI快讯，有投资者在投资者互动平台提问：三诺生物与腾讯医疗合作开发"AI +脑机"糖尿病管理平 台，用户超200万，通过与互联网企业合作，积累了大量相关数据以及数据处理经验。此外，公司还与 强脑科技在光遗传学的闭环脑机接口系统上展开合作，积极拓展脑机接口领域业务，为数据采集转化技 术发展提供助力。三诺生物是医疗级脑电信号采集装置核心供应商，自主研发的128通道脑电监测系统 通过CE认证，已用于多家三甲医院的神经科学研究。这些信息真实吗？ 三诺生物（300298.SZ）8月14日在投资者互动平台表示，公司对人工智能领域的技术探索主要聚焦 AI+慢病管理，截至目前公司暂未开展脑机接口领域相关业务，也非医疗级脑电信号采集装置核心供应 商。公司相关信息请以公司官方渠道发布的信息为准，详情可以查询公司官方网站 （www.sinocare.com）和巨潮资讯网（http://www.cninfo.com.cn）发布的有关信息。 （文章来源：每日经济新闻） ...